vs

Side-by-side financial comparison of Abacus Global Management, Inc. (ABX) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Abacus Global Management, Inc. is the larger business by last-quarter revenue ($71.9M vs $70.6M, roughly 1.0× Viridian Therapeutics, Inc.\DE). Abacus Global Management, Inc. runs the higher net margin — 10.1% vs -49.0%, a 59.1% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 116.5%). Abacus Global Management, Inc. produced more free cash flow last quarter ($-26.6M vs $-84.7M).

Abacus Group is a ASX 200 public listed company that specialises in investing in Australian Real estate investment trusts with an investment portfolio concentrated in the Office and Self Storage sectors. They manage legacy investments in property developments. The company was known as Abacus Property Group until August 2023, when they split off their self-storage business, Abacus Storage King.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

ABX vs VRDN — Head-to-Head

Bigger by revenue
ABX
ABX
1.0× larger
ABX
$71.9M
$70.6M
VRDN
Growing faster (revenue YoY)
VRDN
VRDN
+81841.7% gap
VRDN
81958.1%
116.5%
ABX
Higher net margin
ABX
ABX
59.1% more per $
ABX
10.1%
-49.0%
VRDN
More free cash flow
ABX
ABX
$58.1M more FCF
ABX
$-26.6M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ABX
ABX
VRDN
VRDN
Revenue
$71.9M
$70.6M
Net Profit
$7.2M
$-34.6M
Gross Margin
88.8%
Operating Margin
31.7%
-56.7%
Net Margin
10.1%
-49.0%
Revenue YoY
116.5%
81958.1%
Net Profit YoY
139.6%
54.9%
EPS (diluted)
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABX
ABX
VRDN
VRDN
Q4 25
$71.9M
Q3 25
$63.0M
$70.6M
Q2 25
$56.2M
Q1 25
$44.1M
Q4 24
$33.2M
Q3 24
$28.1M
Q2 24
$29.1M
Q1 24
$21.5M
Net Profit
ABX
ABX
VRDN
VRDN
Q4 25
$7.2M
Q3 25
$7.1M
$-34.6M
Q2 25
$17.6M
Q1 25
$4.6M
Q4 24
$-18.3M
Q3 24
$-5.1M
Q2 24
$770.0K
Q1 24
$-1.3M
Gross Margin
ABX
ABX
VRDN
VRDN
Q4 25
88.8%
Q3 25
87.8%
Q2 25
89.2%
Q1 25
83.9%
Q4 24
88.8%
Q3 24
92.2%
Q2 24
90.6%
Q1 24
87.3%
Operating Margin
ABX
ABX
VRDN
VRDN
Q4 25
31.7%
Q3 25
35.6%
-56.7%
Q2 25
40.1%
Q1 25
47.6%
Q4 24
-50.5%
Q3 24
24.3%
Q2 24
23.3%
Q1 24
10.5%
Net Margin
ABX
ABX
VRDN
VRDN
Q4 25
10.1%
Q3 25
11.2%
-49.0%
Q2 25
31.3%
Q1 25
10.5%
Q4 24
-55.0%
Q3 24
-18.2%
Q2 24
2.6%
Q1 24
-6.3%
EPS (diluted)
ABX
ABX
VRDN
VRDN
Q4 25
$0.06
Q3 25
$0.07
Q2 25
$0.18
Q1 25
$0.05
Q4 24
$-0.26
Q3 24
$-0.07
Q2 24
$0.01
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABX
ABX
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$38.1M
$490.9M
Total DebtLower is stronger
$405.8M
Stockholders' EquityBook value
$418.5M
$503.0M
Total Assets
$902.2M
$577.1M
Debt / EquityLower = less leverage
0.97×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABX
ABX
VRDN
VRDN
Q4 25
$38.1M
Q3 25
$86.4M
$490.9M
Q2 25
$74.8M
Q1 25
$43.8M
Q4 24
$131.9M
Q3 24
$19.4M
Q2 24
$91.3M
Q1 24
$65.4M
Total Debt
ABX
ABX
VRDN
VRDN
Q4 25
$405.8M
Q3 25
$409.3M
Q2 25
Q1 25
Q4 24
$380.8M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABX
ABX
VRDN
VRDN
Q4 25
$418.5M
Q3 25
$434.6M
$503.0M
Q2 25
$416.5M
Q1 25
$430.6M
Q4 24
$423.3M
Q3 24
$257.9M
Q2 24
$256.8M
Q1 24
$165.3M
Total Assets
ABX
ABX
VRDN
VRDN
Q4 25
$902.2M
Q3 25
$918.9M
$577.1M
Q2 25
$848.4M
Q1 25
$856.5M
Q4 24
$874.2M
Q3 24
$477.3M
Q2 24
$483.9M
Q1 24
$376.7M
Debt / Equity
ABX
ABX
VRDN
VRDN
Q4 25
0.97×
Q3 25
0.94×
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABX
ABX
VRDN
VRDN
Operating Cash FlowLast quarter
$-25.7M
$-84.6M
Free Cash FlowOCF − Capex
$-26.6M
$-84.7M
FCF MarginFCF / Revenue
-37.0%
-120.1%
Capex IntensityCapex / Revenue
1.3%
0.2%
Cash ConversionOCF / Net Profit
-3.55×
TTM Free Cash FlowTrailing 4 quarters
$-45.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABX
ABX
VRDN
VRDN
Q4 25
$-25.7M
Q3 25
$-32.8M
$-84.6M
Q2 25
$76.1M
Q1 25
$-61.6M
Q4 24
$-208.8M
Q3 24
$-52.3M
Q2 24
$-67.1M
Q1 24
$2.5M
Free Cash Flow
ABX
ABX
VRDN
VRDN
Q4 25
$-26.6M
Q3 25
$-32.9M
$-84.7M
Q2 25
$75.7M
Q1 25
$-61.8M
Q4 24
$-209.6M
Q3 24
$-52.5M
Q2 24
$-67.2M
Q1 24
$2.4M
FCF Margin
ABX
ABX
VRDN
VRDN
Q4 25
-37.0%
Q3 25
-52.3%
-120.1%
Q2 25
134.6%
Q1 25
-140.0%
Q4 24
-631.1%
Q3 24
-186.6%
Q2 24
-231.3%
Q1 24
10.9%
Capex Intensity
ABX
ABX
VRDN
VRDN
Q4 25
1.3%
Q3 25
0.3%
0.2%
Q2 25
0.8%
Q1 25
0.5%
Q4 24
2.4%
Q3 24
0.9%
Q2 24
0.7%
Q1 24
0.8%
Cash Conversion
ABX
ABX
VRDN
VRDN
Q4 25
-3.55×
Q3 25
-4.63×
Q2 25
4.33×
Q1 25
-13.28×
Q4 24
Q3 24
Q2 24
-87.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABX
ABX

Life Solutions Segment$63.0M88%
Asset Management Segment$8.7M12%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons